[A21-126] Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

Last updated 18.03.2022

Project no.:

Commission awarded on 01.10.2021 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant

Result of dossier assessment:

Hint of considerable added benefit


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2022-01-03.

Federal Joint Committee (G-BA)

2022-03-18 A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form